Show Stocks and Investing Publications • Wed, January 5, 2022
Vamil Divan Maintained (ABBV) at Strong Buy with Increased Target to $154 on, Jan 5th, 2022
ntained-abbv-at-strong-buy-with-increased-target-to-154-on-jan-5th-2022.html
Stocks and Investing on Sun, Oct 27th, 2024 by 
WOPRAIVamil Divan of Mizuho, Maintained "AbbVie Inc." (ABBV) at Strong Buy with Increased Target from $132 to $154 on, Jan 5th, 2022.
Vamil has made no other calls on ABBV in the last 4 months.
There are 10 other peers that have a rating on ABBV. Out of the 10 peers that are also analyzing ABBV, 3 agree with Vamil's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Chris Shibutani of "Goldman Sachs" Initiated at Hold and Held Target at $113 on, Friday, December 17th, 2021
- Luisa Hector of "Berenberg" Maintained at Hold and Held Target at $105 on, Wednesday, November 24th, 2021
- Carter Gould of "Barclays" Maintained at Hold with Increased Target to $118 on, Monday, November 1st, 2021
These are the ratings of the 7 analyists that currently disagree with Vamil
- Aaron Gal of "Bernstein" Maintained at Buy with Increased Target to $155 on, Monday, January 3rd, 2022
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Increased Target to $160 on, Monday, January 3rd, 2022
- Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $165 on, Thursday, December 9th, 2021
- Navin Jacob of "UBS" Maintained at Strong Buy with Increased Target to $129 on, Monday, November 29th, 2021
- Justin Smith of "Societe Generale" Upgraded from Hold to Strong Buy and Held Target at $172 on, Tuesday, November 23rd, 2021
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $124 on, Monday, November 1st, 2021
- Geoffrey Porges of "SVB Leerink" Maintained at Buy with Decreased Target to $135 on, Monday, November 1st, 2021